Confirmatory overall survival analysis of CLEOPATRA: a randomized, doubleblind, placebo-controlled phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first-line metastatic breast cancer

NE Oncology Issue – April 2013 Swain S, et al. SABCS 2012:P5-18-26 Background The CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) study randomized patients with human epidermal growth factor receptor 2 (HER2)- positive first-line metastatic breast...